 | • レポートコード：MRC23Q36353 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、94ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥406,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥812,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のセザリー症候群治療市場について調査・分析し、世界のセザリー症候群治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（放射線療法、化学療法、免疫療法、体外光化学療法）、用途別セグメント分析（病院、専門クリニック、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Innate Pharma、Kyowa Kirin、Shionogi、Bioniz Therapeutics、Eisai、Bayer、Minophagen Pharmaceutical Co., Ltd、Novartis、STI Pharma、Gilead、Merck、Hikma、Seattle Genetics、Amerigen Pharmaceuticalsなどが含まれています。世界のセザリー症候群治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、セザリー症候群治療市場規模を推定する際に考慮しました。本レポートは、セザリー症候群治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、セザリー症候群治療に関するビジネス上の意思決定に役立てることを目的としています。 ・セザリー症候群治療市場の概要 - セザリー症候群治療のタイプ別セグメント - 世界のセザリー症候群治療市場規模：タイプ別分析（放射線療法、化学療法、免疫療法、体外光化学療法） - セザリー症候群治療の用途別セグメント - 世界のセザリー症候群治療市場規模：用途別分析（病院、専門クリニック、その他） - 世界のセザリー症候群治療市場規模予測（2018年-2029年） ・セザリー症候群治療市場の成長トレンド - セザリー症候群治療の地域別市場規模（2018年-2029年） - セザリー症候群治療市場ダイナミクス - セザリー症候群治療の業界動向 - セザリー症候群治療市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：放射線療法、化学療法、免疫療法、体外光化学療法 - 世界のセザリー症候群治療のタイプ別市場規模（2018年-2023年） - 世界のセザリー症候群治療のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、専門クリニック、その他 - 世界のセザリー症候群治療の用途別市場規模（2018年-2023年） - 世界のセザリー症候群治療の用途別市場規模（2024年-2029年） ・セザリー症候群治療の地域別市場規模 - 北米のセザリー症候群治療市場規模（2018年-2029年） - アメリカのセザリー症候群治療市場規模（2018年-2029年） - ヨーロッパのセザリー症候群治療市場規模（2018年-2029年） - アジア太平洋のセザリー症候群治療市場規模（2018年-2029年） - 中国のセザリー症候群治療市場規模（2018年-2029年） - 日本のセザリー症候群治療市場規模（2018年-2029年） - 韓国のセザリー症候群治療市場規模（2018年-2029年） - インドのセザリー症候群治療市場規模（2018年-2029年） - オーストラリアのセザリー症候群治療市場規模（2018年-2029年） - 中南米のセザリー症候群治療市場規模（2018年-2029年） - 中東・アフリカのセザリー症候群治療市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Innate Pharma、Kyowa Kirin、Shionogi、Bioniz Therapeutics、Eisai、Bayer、Minophagen Pharmaceutical Co., Ltd、Novartis、STI Pharma、Gilead、Merck、Hikma、Seattle Genetics、Amerigen Pharmaceuticals ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Sezary Syndrome Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Sezary Syndrome Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Sezary Syndrome Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Sezary Syndrome Treatment in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Sezary Syndrome Treatment include Innate Pharma, Kyowa Kirin, Shionogi, Bioniz Therapeutics, Eisai, Bayer, Minophagen Pharmaceutical Co., Ltd, Novartis and STI Pharma, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Sezary Syndrome Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sezary Syndrome Treatment.
The Sezary Syndrome Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Sezary Syndrome Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Sezary Syndrome Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Innate Pharma
Kyowa Kirin
Shionogi
Bioniz Therapeutics
Eisai
Bayer
Minophagen Pharmaceutical Co., Ltd
Novartis
STI Pharma
Gilead
Merck
Hikma
Seattle Genetics
Amerigen Pharmaceuticals
Segment by Type
Radiation therapy
Chemotherapy
Immunotherapy
Extracorporeal Photochemotherapy
Segment by Application
Hospital
Specialist Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sezary Syndrome Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Sezary Syndrome Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Radiation therapy
1.2.3 Chemotherapy
1.2.4 Immunotherapy
1.2.5 Extracorporeal Photochemotherapy
1.3 Market by Application
1.3.1 Global Sezary Syndrome Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Specialist Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Sezary Syndrome Treatment Market Perspective (2018-2029)
2.2 Sezary Syndrome Treatment Growth Trends by Region
2.2.1 Global Sezary Syndrome Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Sezary Syndrome Treatment Historic Market Size by Region (2018-2023)
2.2.3 Sezary Syndrome Treatment Forecasted Market Size by Region (2024-2029)
2.3 Sezary Syndrome Treatment Market Dynamics
2.3.1 Sezary Syndrome Treatment Industry Trends
2.3.2 Sezary Syndrome Treatment Market Drivers
2.3.3 Sezary Syndrome Treatment Market Challenges
2.3.4 Sezary Syndrome Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Sezary Syndrome Treatment Players by Revenue
3.1.1 Global Top Sezary Syndrome Treatment Players by Revenue (2018-2023)
3.1.2 Global Sezary Syndrome Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Sezary Syndrome Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Sezary Syndrome Treatment Revenue
3.4 Global Sezary Syndrome Treatment Market Concentration Ratio
3.4.1 Global Sezary Syndrome Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Sezary Syndrome Treatment Revenue in 2022
3.5 Sezary Syndrome Treatment Key Players Head office and Area Served
3.6 Key Players Sezary Syndrome Treatment Product Solution and Service
3.7 Date of Enter into Sezary Syndrome Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Sezary Syndrome Treatment Breakdown Data by Type
4.1 Global Sezary Syndrome Treatment Historic Market Size by Type (2018-2023)
4.2 Global Sezary Syndrome Treatment Forecasted Market Size by Type (2024-2029)
5 Sezary Syndrome Treatment Breakdown Data by Application
5.1 Global Sezary Syndrome Treatment Historic Market Size by Application (2018-2023)
5.2 Global Sezary Syndrome Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Sezary Syndrome Treatment Market Size (2018-2029)
6.2 North America Sezary Syndrome Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Sezary Syndrome Treatment Market Size by Country (2018-2023)
6.4 North America Sezary Syndrome Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Sezary Syndrome Treatment Market Size (2018-2029)
7.2 Europe Sezary Syndrome Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Sezary Syndrome Treatment Market Size by Country (2018-2023)
7.4 Europe Sezary Syndrome Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Sezary Syndrome Treatment Market Size (2018-2029)
8.2 Asia-Pacific Sezary Syndrome Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Sezary Syndrome Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Sezary Syndrome Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Sezary Syndrome Treatment Market Size (2018-2029)
9.2 Latin America Sezary Syndrome Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Sezary Syndrome Treatment Market Size by Country (2018-2023)
9.4 Latin America Sezary Syndrome Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Sezary Syndrome Treatment Market Size (2018-2029)
10.2 Middle East & Africa Sezary Syndrome Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Sezary Syndrome Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Sezary Syndrome Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Innate Pharma
11.1.1 Innate Pharma Company Detail
11.1.2 Innate Pharma Business Overview
11.1.3 Innate Pharma Sezary Syndrome Treatment Introduction
11.1.4 Innate Pharma Revenue in Sezary Syndrome Treatment Business (2018-2023)
11.1.5 Innate Pharma Recent Development
11.2 Kyowa Kirin
11.2.1 Kyowa Kirin Company Detail
11.2.2 Kyowa Kirin Business Overview
11.2.3 Kyowa Kirin Sezary Syndrome Treatment Introduction
11.2.4 Kyowa Kirin Revenue in Sezary Syndrome Treatment Business (2018-2023)
11.2.5 Kyowa Kirin Recent Development
11.3 Shionogi
11.3.1 Shionogi Company Detail
11.3.2 Shionogi Business Overview
11.3.3 Shionogi Sezary Syndrome Treatment Introduction
11.3.4 Shionogi Revenue in Sezary Syndrome Treatment Business (2018-2023)
11.3.5 Shionogi Recent Development
11.4 Bioniz Therapeutics
11.4.1 Bioniz Therapeutics Company Detail
11.4.2 Bioniz Therapeutics Business Overview
11.4.3 Bioniz Therapeutics Sezary Syndrome Treatment Introduction
11.4.4 Bioniz Therapeutics Revenue in Sezary Syndrome Treatment Business (2018-2023)
11.4.5 Bioniz Therapeutics Recent Development
11.5 Eisai
11.5.1 Eisai Company Detail
11.5.2 Eisai Business Overview
11.5.3 Eisai Sezary Syndrome Treatment Introduction
11.5.4 Eisai Revenue in Sezary Syndrome Treatment Business (2018-2023)
11.5.5 Eisai Recent Development
11.6 Bayer
11.6.1 Bayer Company Detail
11.6.2 Bayer Business Overview
11.6.3 Bayer Sezary Syndrome Treatment Introduction
11.6.4 Bayer Revenue in Sezary Syndrome Treatment Business (2018-2023)
11.6.5 Bayer Recent Development
11.7 Minophagen Pharmaceutical Co., Ltd
11.7.1 Minophagen Pharmaceutical Co., Ltd Company Detail
11.7.2 Minophagen Pharmaceutical Co., Ltd Business Overview
11.7.3 Minophagen Pharmaceutical Co., Ltd Sezary Syndrome Treatment Introduction
11.7.4 Minophagen Pharmaceutical Co., Ltd Revenue in Sezary Syndrome Treatment Business (2018-2023)
11.7.5 Minophagen Pharmaceutical Co., Ltd Recent Development
11.8 Novartis
11.8.1 Novartis Company Detail
11.8.2 Novartis Business Overview
11.8.3 Novartis Sezary Syndrome Treatment Introduction
11.8.4 Novartis Revenue in Sezary Syndrome Treatment Business (2018-2023)
11.8.5 Novartis Recent Development
11.9 STI Pharma
11.9.1 STI Pharma Company Detail
11.9.2 STI Pharma Business Overview
11.9.3 STI Pharma Sezary Syndrome Treatment Introduction
11.9.4 STI Pharma Revenue in Sezary Syndrome Treatment Business (2018-2023)
11.9.5 STI Pharma Recent Development
11.10 Gilead
11.10.1 Gilead Company Detail
11.10.2 Gilead Business Overview
11.10.3 Gilead Sezary Syndrome Treatment Introduction
11.10.4 Gilead Revenue in Sezary Syndrome Treatment Business (2018-2023)
11.10.5 Gilead Recent Development
11.11 Merck
11.11.1 Merck Company Detail
11.11.2 Merck Business Overview
11.11.3 Merck Sezary Syndrome Treatment Introduction
11.11.4 Merck Revenue in Sezary Syndrome Treatment Business (2018-2023)
11.11.5 Merck Recent Development
11.12 Hikma
11.12.1 Hikma Company Detail
11.12.2 Hikma Business Overview
11.12.3 Hikma Sezary Syndrome Treatment Introduction
11.12.4 Hikma Revenue in Sezary Syndrome Treatment Business (2018-2023)
11.12.5 Hikma Recent Development
11.13 Seattle Genetics
11.13.1 Seattle Genetics Company Detail
11.13.2 Seattle Genetics Business Overview
11.13.3 Seattle Genetics Sezary Syndrome Treatment Introduction
11.13.4 Seattle Genetics Revenue in Sezary Syndrome Treatment Business (2018-2023)
11.13.5 Seattle Genetics Recent Development
11.14 Amerigen Pharmaceuticals
11.14.1 Amerigen Pharmaceuticals Company Detail
11.14.2 Amerigen Pharmaceuticals Business Overview
11.14.3 Amerigen Pharmaceuticals Sezary Syndrome Treatment Introduction
11.14.4 Amerigen Pharmaceuticals Revenue in Sezary Syndrome Treatment Business (2018-2023)
11.14.5 Amerigen Pharmaceuticals Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details